Xeljanz was approved under the supplemental New Drug Application, according to a Dec. 14 news release. The approval was based on a phase 3 trial in 269 adults with active ankylosing spondylitis.
“This regulatory approval affirms the clinical value and versatility of Xeljanz, the first and only Janus kinase inhibitor approved for five indications in the United States for the treatment of patients with certain immuno-inflammatory conditions,” Mike Gladstone, Pfizer’s global president of inflammation and immunology, said in the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
